Waddah Arafat, MD, discusses how the use of neoadjuvant chemotherapy in MIBC has changed relative to the addition of immunotherapy to this paradigm.
Waddah Arafat, MD
Advertisement
Waddah Arafat, MD, is an associate professor of internal medicine and a member of the Division of Hematology and Oncology at the University of Texas (UT) Southwestern Medical Center; as well as medical director of the Clinical Cancer Informatics Program at the UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Articles by Waddah Arafat, MD
Advertisement
Latest Updated Articles
Dr Arafat on Evolving Neoadjuvant Treatment Strategies in MIBCAugust 29th 2025
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
The OncFive: Top Oncology Articles for the Week of 5/31
5